Articles From: On Valentine’s Day, UPS Plays ‘Matchmaker’ for Millions Worldwide to Oncolytics Biotech® Inc. Announces 2012 Year End Results


2013/2/11
Forget Cupid.
Sign-up for On Valentine’s Day, UPS Plays ‘Matchmaker’ for Millions Worldwide investment picks
2013/2/4
On World Cancer Day Holland America Line Launches 'On Deck for a Cause' Shipboard Fundraising Program Supporting Six International Cancer Organizations Canada NewsWire New walk on 500 cruises annually to raise money for the global fight against cancer SEATTLE , Feb.
Sign-up for On World Cancer Day Holland America Line Launches 'On Deck for a Cause' Shipboard Fundraising Program Supporting Six International Cancer Organizations investment picks
2013/2/4
New walk on 500 cruises annually to raise money for the global fight against cancer SEATTLE , Feb.
Sign-up for On World Cancer Day Holland America Line Launches 'On Deck for a Cause' Shipboard Fundraising Program Supporting Six International Cancer Organizations investment picks
2013/4/10
TEL AVIV, Israel and SYDNEY, Australia, April 10, 2013 (GLOBE NEWSWIRE) -- Top Image Systems, Ltd.
Sign-up for On-Line Financial Services Provider SuperIQ Goes Live With Top Image Systems' eFLOW(R) Digital Mailroom Solution investment picks
2013/3/5
AT&T Unified Communications Connects Today's Mobile Worker With the Click of a Button LONDON , March 5, 2013 /PRNewswire/ -- Technology continues to bring the global business community closer together, enabling employees to collaborate effectively without having to be in the same office space – or even the same country.
Sign-up for On-The-Go Collaboration Made Easy For Global Businesses investment picks
2013/4/25
Genzyme , a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today positive top-line results from the TOPIC trial for AUBAGIO (teriflunomide). The trial was designed to assess whether early initiation of AUBAGIO (teriflunomide) in patients who experienced their first neurological symptoms consistent with Clinically Isolated Syndrome (CIS) can prevent or delay conversion to clinically definite multiple sclerosis (CDMS). Clinically isolated syndrome (CIS) is defined as a first clinical attack with features suggestive of MS.
Sign-up for Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC Study investment picks
2013/2/12
OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer Canada NewsWire Company Reaffirms Commitment to Addressing Treatment Resistance in Genitourinary (GU) Cancers with Fourth Phase 2 GU trial in OGX-427 ORCA Program BOTHELL, Wash.
Sign-up for OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer investment picks
2013/2/12
Company Reaffirms Commitment to Addressing Treatment Resistance in Genitourinary (GU) Cancers with Fourth Phase 2 GU trial in OGX-427 ORCA Program BOTHELL, Wash.
Sign-up for OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer investment picks
2013/5/1
OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer Canada NewsWire Pancreatic Cancer Becomes the Fourth Tumor Type Evaluated as Part of the OGX-427 ORCA™ Program, In Addition to Bladder, Lung and Prostate Cancers BOTHELL, Wash.
Sign-up for OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer investment picks
2013/5/1
Pancreatic Cancer Becomes the Fourth Tumor Type Evaluated as Part of the OGX-427 ORCA™ Program, In Addition to Bladder, Lung and Prostate Cancers BOTHELL, Wash.
Sign-up for OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer investment picks
2013/4/11
OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer Canada NewsWire Company Expands Development Program with Fifth Phase 2 Clinical Trial in the OGX-427 ORCA™ Program BOTHELL, Wash.
Sign-up for OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer investment picks
2013/4/11
Company Expands Development Program with Fifth Phase 2 Clinical Trial in the OGX-427 ORCA™ Program BOTHELL, Wash.
Sign-up for OncoGenex Announces Plans for the Initiation of the Spruce™ Clinical Trial Evaluating OGX-427 in Combination with Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer investment picks
2013/4/30
OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment Canada NewsWire The OGX-427 ORCA™ Program Continues to Expand with Patient Enrollment Now Open for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer BOTHELL, Wash.
Sign-up for OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment investment picks
2013/4/30
The OGX-427 ORCA™ Program Continues to Expand with Patient Enrollment Now Open for Second Phase 2 Trial of OGX-427 in Advanced Bladder Cancer BOTHELL, Wash.
Sign-up for OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment investment picks
2013/3/28
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference Canada NewsWire A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at  www.oncogenex.com .
Sign-up for OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference investment picks
2013/3/28
BOTHELL, WA and VANCOUVER , March 28, 2013 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc.  (NASDAQ: OGXI) announced today that Scott Cormack , President and Chief Executive Officer, will provide a corporate presentation at the Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 9:30 a.m. ET at the Millennium Broadway Hotel in New York City .
Sign-up for OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference investment picks
2013/4/23
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference Canada NewsWire A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at  www.oncogenex.com .
Sign-up for OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference investment picks
2013/4/23
BOTHELL, WA and VANCOUVER, BC , April 23, 2013 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc.  (NASDAQ: OGXI) announced today that Scott Cormack , President and Chief Executive Officer, will provide a corporate presentation at the Needham Annual Healthcare Conference on Tuesday, April 30, 2013 at 11:20 a.m. ET at the Westin New York Grand Central Hotel in New York City .
Sign-up for OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference investment picks
2013/2/5
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences Canada NewsWire Live audio webcasts can be accessed through the Investor Relations page of the OncoGenex website at  www.oncogenex.com .
Sign-up for OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences investment picks
2013/2/5
BOTHELL, WA and VANCOUVER , Feb.
Sign-up for OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences investment picks
2013/5/2
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 Canada NewsWire Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 investment picks
2013/5/2
Conference call to be held on Thursday, May 2 at 4:30pm Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 investment picks
2013/3/7
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012 Canada NewsWire Conference call to be held on Thursday, March 7, 2013 at 4:30 p.m. Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012 investment picks
2013/3/7
Conference call to be held on Thursday, March 7, 2013 at 4:30 p.m. Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012 investment picks
2013/4/25
OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013 Canada NewsWire To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com .
Sign-up for OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013 investment picks
2013/4/25
BOTHELL, WA and VANCOUVER, BC , April 25, 2013 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's first quarter 2013 financial results will be released on Thursday, May 2, 2013 , and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon.
Sign-up for OncoGenex to Webcast Discussion of Clinical Development Program and First Quarter 2013 Financial Results on May 2, 2013 investment picks
2013/2/28
OncoGenex to Webcast Update on Clinical Development Program and Discussion of Fourth Quarter and Full Year 2012 Financial Results on Thursday, March 7, 2013 Canada NewsWire To access the webcast, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com .
Sign-up for OncoGenex to Webcast Update on Clinical Development Program and Discussion of Fourth Quarter and Full Year 2012 Financial Results on Thursday, March 7, 2013 investment picks
2013/3/14
Oncolytics Biotech® Inc. Announces 2012 Year End Results Canada NewsWire CALGARY , March 14, 2013 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the  year ended December 31, 2012 .
Sign-up for Oncolytics Biotech® Inc. Announces 2012 Year End Results investment picks
2013/3/14
CALGARY , March 14, 2013 /PRNewswire/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the  year ended December 31, 2012 .
Sign-up for Oncolytics Biotech® Inc. Announces 2012 Year End Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: On Valentine’s Day, UPS Plays ‘Matchmaker’ for Millions Worldwide to Oncolytics Biotech® Inc. Announces 2012 Year End Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity